Carphedon
From Wikipedia, the free encyclopedia
|
|
|
| IUPAC name: 2-(4-phenyl-2-oxopyrrolidin-1-yl)acetamide |
|
| CAS number 77472–70–9 |
ATC code ? |
| Chemical formula | C12H14N2O2 |
| Molecular weight | 218.3 |
| Melting point | ? |
| Bioavailability | near 1 |
| Metabolism | ? |
| Elimination half life | 3-5 hours |
| Excretion | ? |
| Pregnancy category | ? |
| Legal status | Available by perscription |
| Delivery | Oral |
Carphedon (C12H14N2O2, 2-(4-phenyl-2-oxopyrrolidin-1-yl)acetamide) is a derivative of the nootropic drug Piracetam. It was developed in Russia, and a small number of low-scale clinical studies have shown possible links between prescription of Carphedon and improvement in a number of encephalopathic conditions, including lesions of cerebral blood pathways, and certain types of glioma. It is also claimed to increase physical stamina and provide improved tolerance to cold. As a result, it appears on the lists of banned substances issued by the World Anti-Doping Agency. This list is applicable in all Olympic sports. As of 27 February 2006, the most recent case of Carphedon abuse by a professional athlete is that of Russian biathlon Olympic silver medalist Olga Pyleva in the 2006 Winter Olympics, who was disqualified from attending further events following a positive drug test. She was subsequently banned from competition for two years. It may be noteworthy that Pyleva claims that Carphedon was an unlisted ingredient of a Russian medication she was prescribed by her personal doctor (not a team doctor).
While not widely available in the West, in Russia it is available as a prescription medicine under the brand name "Phenotropil". Packets of 10 100mg pills are available for roughly 330 rubles (2006 price). It is typically prescribed as a general stimulant or to increase tolerance to cold and stress.
A former rider for Gerolsteiner, professional cyclist Danilo Hondo, tested positive to this banned substance in 2005.
[edit] External links
- "Super Speed" from Vice Magazine's Russian issue
- *An interview with Danilo Hondo, 15-Jun-06* from Cyclingnews
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
